Details
SOM Biotech is a clinical-stage drug discovery and development company based in Barcelona, Spain, with an office in the US, focused on repurposing drugs for CNS orphan indications. Its drug discovery is based on a proprietary artificial intelligence repurposing technology which has demonstrated success through the worldwide licensing of the company's asset for TTR-Amyloidosis to a pharmaceutical company based in the US.
Currently, SOM Biotech has two clinical-stage assets for Huntington's Disease (SOM3355) and Adrenoleukodystrophy (SOM1201), as well as a pool of preclinical-stage assets. SOM Biotech seeks strategic collaborations through licensing of its clinical-stage assets and co-development of new projects.